Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Reumatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
INTERVENTIONAL
Inicio: 1 de jun de 2011
ID: NCT01365455
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 2 de ago de 2018
ID: NCT03616964
Completado
Fase 3
ClinicalTrials.gov
A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de jun de 2005
ID: NCT00175877
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
INTERVENTIONAL
Inicio: 22 de dic de 2014
ID: NCT02277444
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
INTERVENTIONAL
Inicio: 27 de sept de 2022
ID: NCT05503264
Completado
Fase 4
ClinicalTrials.gov
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids
INTERVENTIONAL
Inicio: 16 de dic de 2016
ID: NCT02953821
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis
INTERVENTIONAL
Inicio: 15 de feb de 2018
ID: NCT03217422
Completado
Fase 3
ClinicalTrials.gov
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
INTERVENTIONAL
Inicio: 15 de dic de 2015
ID: NCT02549170
Completado
Fase 3
ClinicalTrials.gov
An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever
INTERVENTIONAL
Inicio: 1 de sept de 2009
ID: NCT00891046
Reclutando
ClinicalTrials.gov
Prospective Registry of Patients With Systemic Lupus Erythematosus of the Argentinian Society of Rheumatology
OBSERVATIONAL
Inicio: 1 de abr de 2022
ID: NCT05470569
Terminado
Fase 3
ClinicalTrials.gov
A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)
INTERVENTIONAL
Inicio: 1 de jun de 2007
ID: NCT00430677
Activo, no recluta
Fase 1
ClinicalTrials.gov
An Open Label Phase 1b Study of Felzartamab in Lupus Nephritis
INTERVENTIONAL
Inicio: 1 de nov de 2023
ID: NCT06064929
Completado
Fase 3
ClinicalTrials.gov
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
INTERVENTIONAL
Inicio: 1 de mar de 2010
ID: NCT01087762
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
INTERVENTIONAL
Inicio: 1 de dic de 2015
ID: NCT02629159
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg With Placebo in Patients With Active Lupus Nephritis
INTERVENTIONAL
Inicio: 3 de nov de 2023
ID: NCT05781750
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Randomized, Double-blind, Controlled Study to Evaluate the Immune Responses, Safety and Clinical Efficacy of Three Doses of Neovacs' TNF-Kinoid in Adult Patients With Rheumatoid Arthritis Who Have Relapsed Despite Anti-TNFα Biological Therapy
INTERVENTIONAL
Inicio: 1 de dic de 2009
ID: NCT01040715
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 4 de jul de 2017
ID: NCT03120949
Completado
Fase 2
ClinicalTrials.gov
A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy
INTERVENTIONAL
Inicio: 1 de ago de 2009
ID: NCT00966875
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de oct de 2009
ID: NCT00929864
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy
INTERVENTIONAL
Inicio: 12 de jul de 2024
ID: NCT06290128
Anterior
1
...
16
17
18
...
434
Siguiente
Filtros